Aventis Pharma (erstwhile Hoechst Marion) seems to be taking the right steps to inculcate much wanted growth in the company. While operating margins are on a steady rise, product portfolio of the company is increasingly becoming enviable. The company is slowly and steadily shifting its focus towards high margin specialised therapeutic segments. The DPCO order unfortunately seems to be acting as a dampener for the company's valuations.
The operating margins of the company have been on an upward spiral thanks to the restructuring benefits and new product introductions. Aventis is slowly transforming from a company concentrated mainly on anti-infectives and pain management to a company specialising in life style therapeutic segments, where the margins are comparatively higher.
The company is also expected to benefit from global bulk outsourcing by its parent company. The company’s Ankleshwar unit is already used by the parent company for this purpose as a sourcing base for a couple of bulk drugs (Ramipril and Articaine). It is expected that outsourcing by the parent company from HMR’s Goa plant would kick off shortly. This would be for Daonil (a leading product in anti-diabetic segment) from India for its European operations.
However, going forward, we expect the company to show spikes in the margins based on product introductions. Further, though the company's product enjoys strong brand recall, it faces stiff competition from other domestic brands and generic products. For example, incase of Amaryl (anti-diabetic), there are already several generic competing products, which are priced below Amaryl. In a country like India where markets are absolutely price sensitive, premium pricing is difficult to continue. Thus, if the margins are to remain buoyant, product introductions will need to be strong. Going by the past experience the company has always benefited from fast product launches by its parent company.
The effect of the proposed change in the DPCO is expected to be mixed. Some of its top selling drugs, covering around 10% of the total sales of the company are expected to go out of price control. However, Daonil, the company’s top selling anti-diabetic product is expected to come under DPCO coverage. Daonil contributes around 11% of the total sales of the company. Though the DPCO coverage of the company still remains high at around 35%, it is expected to drop sharply going forward inline with the change in the revenue structure.
At the current market price of Rs 361, the stock trades at a P/E of 10.4x its FY02 earnings. The slide in the price of the stock seems to be on account of successive disappointments on non-relaxation of DPCO in favour of the company. However, considering the growth prospects and comparative valuations with the peers, the stock looks attractive at the current price.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407